Literature DB >> 16870249

Activating Notch1 mutations are an early event in T-cell malignancy of Ikaros point mutant Plastic/+ mice.

Simon Mantha1, Maureen Ward, Jonathan McCafferty, Alan Herron, Teresa Palomero, Adolfo Ferrando, Arthur Bank, Christine Richardson.   

Abstract

Ikaros and Notch1 genes are critical to T-cell differentiation through transcriptional activation of target genes and interaction with chromatin remodeling complexes. An Ikaros (Plastic) point mutation inhibits activity of normal Ikaros and Ikaros family members, and leads to T-cell lymphoma in heterozygotes (Plstc/+). Analysis revealed Notch1 activating mutations in 12 of 17 Plstc/+ lymphomas (70%), analogous to those in human T-ALL. Mice acquired Notch1 mutations in lymph nodes as early as 7 weeks. Thus, combined Notch1 and Ikaros dysfunction can be a significant early event in T-cell proliferation and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870249     DOI: 10.1016/j.leukres.2006.06.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

1.  Ikaros is required to survive positive selection and to maintain clonal diversity during T-cell development in the thymus.

Authors:  Kevin W Tinsley; Changwan Hong; Megan A Luckey; Joo-Young Park; Grace Y Kim; Hee-Won Yoon; Hilary R Keller; Andrew J Sacks; Lionel Feigenbaum; Jung-Hyun Park
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

2.  Role of Ikaros in T-cell acute lymphoblastic leukemia.

Authors:  Philippe Kastner; Susan Chan
Journal:  World J Biol Chem       Date:  2011-06-26

3.  Cell of origin strongly influences genetic selection in a mouse model of T-ALL.

Authors:  Katherine E Berquam-Vrieze; Kishore Nannapaneni; Benjamin T Brett; Linda Holmfeldt; Jing Ma; Oksana Zagorodna; Nancy A Jenkins; Neal G Copeland; David K Meyerholz; C Michael Knudson; Charles G Mullighan; Todd E Scheetz; Adam J Dupuy
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

Review 4.  Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies.

Authors:  Jon C Aster; Stephen C Blacklow; Warren S Pear
Journal:  J Pathol       Date:  2010-10-21       Impact factor: 7.996

5.  Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.

Authors:  Monique Dail; Qing Li; Andrew McDaniel; Jason Wong; Keiko Akagi; Ben Huang; Hio Chung Kang; Scott C Kogan; Kevan Shokat; Linda Wolff; Benjamin S Braun; Kevin Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

6.  Notch target gene deregulation and maintenance of the leukemogenic phenotype do not require RBP-J kappa in Ikaros null mice.

Authors:  Sheila Chari; Sarah E Umetsu; Susan Winandy
Journal:  J Immunol       Date:  2010-05-28       Impact factor: 5.422

Review 7.  Notch signaling in leukemia.

Authors:  Jon C Aster; Warren S Pear; Stephen C Blacklow
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

8.  Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis.

Authors:  Pablo Gómez-del Arco; Mariko Kashiwagi; Audrey F Jackson; Taku Naito; Jiangwen Zhang; Feifei Liu; Barbara Kee; Marc Vooijs; Freddy Radtke; Juan Miguel Redondo; Katia Georgopoulos
Journal:  Immunity       Date:  2010-11-24       Impact factor: 31.745

9.  Activated Notch counteracts Ikaros tumor suppression in mouse and human T-cell acute lymphoblastic leukemia.

Authors:  M T Witkowski; L Cimmino; Y Hu; T Trimarchi; H Tagoh; M D McKenzie; S A Best; L Tuohey; T A Willson; S L Nutt; M Busslinger; I Aifantis; G K Smyth; R A Dickins
Journal:  Leukemia       Date:  2015-02-06       Impact factor: 11.528

10.  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.

Authors:  Jennifer O'Neil; Jonathan Grim; Peter Strack; Sudhir Rao; Deanne Tibbitts; Christopher Winter; James Hardwick; Markus Welcker; Jules P Meijerink; Rob Pieters; Giulio Draetta; Rosalie Sears; Bruce E Clurman; A Thomas Look
Journal:  J Exp Med       Date:  2007-07-23       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.